Why Participate in our trials?

Clinical trials study whether or not new medicines, devices, or diagnostic techniques work and are safe for use. Patients choose to participate in clinical trials for a variety of reasons such as a desire to contribute to the greater good through science or access to cutting edge treatments. By participating in clinical trials they are frequently seen by highly trained experts in their field. Compensation for time and effort is sometimes offered for trial participation.

Clinical trials are carefully planned and meticulously reviewed by groups of health specialists called Institutional Review Boards. Patients participate exclusively as volunteers for studies and enroll only after a detailed informed consent process. Patient volunteers have the right to drop out of a trial at any time.

 

CURRENTLY ENROLLING

COPD
Interstitial Lung Disease
Asthma
Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension

For more information on trials or to ask questions contact us here.

We are not currently enrolling for COPD trials, but we are constantly reviewing new studies for future enrollment.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.

Idiopathic Pulmonary Fibrosis
Bellerophon Pulse Technologies LLC-PULSE-PHPF-001

Research Trial

A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (iNO) IN SUBJECTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS ON LONG TERM OXYGEN THERAPY

Purpose: To evaluate the efficacy of iNO as determined by change in 6MWD (6 minute walk distance) in subjects with pulmonary hypertension associated with pulmonary fibrosis (PH-PF) currently receiving treatment with LTOT.

Enroll >

Idiopathic Pulmonary Fibrosis
Biogen MA Inc.
203PF203

Research Trial

A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BG00011 IN PTENTS WITH IDIOPATHIC PULMONARY FIBROSIS

Purpose:  The purpose of this study is to determine the safety and effectiveness of the study drug compared to placebo in subjects with mild to moderate IPF. The study drug will be given by an injection under the skin, also called subcutaneously (SC), once a week for 52 weeks.

Enroll >

Idiopathic Pulmonary Fibrosis
Celgene Corporation
CC-90001-IPF-001

Research Trial

A PHASE 2, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY, WITH AN 28-WEEK ACTIVE TREATMENT EXTENSION, TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS

Purpose: To evaluate the effect of CC-90001, 200 mg and 400 mg, when orally administered (PO) once daily (QD), compared with placebo, on percent of predicted forced vital capacity (FVC) after 24 weeks of treatment in subjects with IPF.

Enroll >

Idiopathic Pulmonary Fibrosis
Galapagos NV
GLPG1690-CL-304

Research Trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF GLPG1690 IN ADDITION TO LOCAL STANDARD OF CARE FOR MINIMUM 52 WEEKS IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS

Purpose: The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated.

Enroll >

Idiopathic Pulmonary Fibrosis
Galecto Biotech AB
GALCATIC-1

Research Trial

A RANDOMIZED, DOUBLE-BLIND, MULICENTRE, PARALLEL, PLACEBO-CONTROLLED PHASE 2B STUDY IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) INVESTIGATING THE EFFICACY AND SAFETY OF TD139, AN INHALED GALECTIN-3 INHIBITOR ADMINISTERED VIA A DRY POWDER INHALER OVER 52 WEEKS.

Purpose: Efficacy of TD139 in subjects treated with standard of care therapy for IPF subjects (or not currently treated with pirfenidone/Nintedanib) by assessing the annual rate of decline in Forced Vital Capacity (FVC; expressed in mL over 52 weeks)

Enroll >

Idiopathic Pulmonary Fibrosis
Respivant Sciences, GmbH
RVT1606-CC-04

Research Trial

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOES-RANGING, EFFICACY AND SAFETY STUDY WITH INHALED RVT-1601 FOR THE TREATMENT OF PERSISTENT COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): SCENIC TRAIL

Purpose: To assess the efficacy of inhaled RVT-1601 in comparison with placebo following 12 weeks of treatment.

Enroll >

We are not currently enrolling for Asthma trials, but we are constantly reviewing new studies for future enrollment.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.

We are not currently enrolling for Interstitial Lung Disease trials, but we are constantly reviewing new studies for future enrollment.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.

Bronchiectasis
Zambon SpA
Z7224L02/Promis II

Research Trial

A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 12 MONTHS OF THERAPY WITH INHALED COLISTIMETHATE SODIUM IN THE TREATMENT OF SUBJECTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA (P. AERUGINOSA)

Purpose: The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non–cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.

 

Enroll> 

We are not currently enrolling for PE/DVT trials, but we are constantly reviewing new studies for future enrollment.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.

Pulmonary Hypertension
United Therapeutics-TDE-HF-301

Research Trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

Purpose:The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24 in subjects with PH associated with HFpEF.

Enroll >